New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] ...

Scientists have uncovered why vaccines can elicit a stronger immune response if they are administered in the same arm.

When it comes to getting the most out of a vaccine, arm consistency can make a difference. Some studies suggest that getting ...

Sophisticated imaging techniques have now revealed that when a booster vaccine is given in the same location, those ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC) in combination with ...

The solid cash conversion allows Telix to internally fund organic growth and flexibility to pursue acquisitions. We expect the company to reinvest the majority of earnings into R&D. We forecast ...

VitriVax, Inc., a formulation technology company, announced a new grant of up to $5M from the Coalition for Epidemic Preparedness Innovations (CEPI). The grant will enable VitriVax to develop the ...

HERVolution Therapeutics ApS ('HERVolution'), a dark genome-focused biotechnology company developing immunotherapies to address aging-related diseases, today announced Tine Gaziel, MD, PhD, has joined ...

While mRNA vaccines represent a transformative platform for infectious disease control, their efficacy in antigen-presenting cells (APCs) remains vulnerable to endogenous regulatory networks, ...